

83. A composition according to claim 38 comprising 3-10 variants.

84. A composition according to claim 83 comprising 4-8 variants.

85. A composition according to claim 84 comprising 5-7 variants.--

### **REMARKS**

Substitute drawings are provided herewith. In accordance with the requirement set forth in the Notice to File Missing Parts that was mailed in the application on August 23, 2002, extraneous text has been removed from the drawings. No new matter has been added by this process.

The specification has been amended to conform it with the substitute drawings and the sequence listing that are submitted herewith.

The descriptions of Figures 2, 8, 12, 15, 17, 18, 19, 22, 23, 24, 25, 26, 28, 29, 30, 31 and 41 have been amended to insert text that was removed from the respective figures as extraneous text. The descriptions of Figures 1, 2, 3, 11, 13, 16 and 31 have been amended to reference the SEQ ID NO: of the respective sequences that were present in the original drawings that are now set forth in the sequence listing. The remaining amendments to the figure descriptions correct obvious typographical errors or conform a description to its respective figure. Hence each respective amended figure description is supported by its description and figure in the application as filed.

The amendment of page 32, lines 8-9 in which --Der p 2-- is substituted for --Bet v 1-- corrects an obvious error. It is clear that the substitutions in mutants A, B and C referred to in the paragraphs immediately following the amended text correspond to Der p 2 substitutions that are set forth in the specification at the paragraph bridging pages 31-32 (see especially page 32, lines 3-6) and page 72, lines 21-21, and that the numbering of the amino acids corresponds to the Der p 2 amino acids set forth in the specification at, e.g., the paragraph bridging pages 31-31, page 72, lines 3-22 and in Table 2 at pages 73-75.

The amendment of the paragraph bridging pages 67-68 is supported in the specification at pages 75-80. SEQ ID NO: 214 merely sets forth in order the Ves v 5 amino acids listed in Table 3 at pages 76-89. It is self evident that the positions of amino acids in SEQ ID NO: 214 correspond to the Ves v 5 amino acid positions recited in the text at page 31, lines 5-

23, page 75, lines 3-15 and page 76, lines 1-16. Accordingly, no new matter is introduced by this amendment.

The paragraph at pages 82-83 has been amended to refer to sequences that were deleted from Figure 18A-B as extraneous text and placed in the sequence listing. The paragraphs at pages 96-97, 104 and 113 have been amended to make reference to the sequences found in Figures 32, 35A-B and 38A-D, respectively. The amendments are supported by the respective Figures filed with application. Accordingly, no new matter is added by these amendments.


The amendments at pages 92, 93, 96, 103 and 112 add new or corrected references to the sequence listing submitted herewith. No new matter is added by this process.

The amendments to the claims are to put the claims in proper form for examination by removing improper multiple dependencies. New claims 68-88 recited subject matter that has been removed from their respective base claims. Accordingly, the amended and newly added claims amend the claims are amended in form only. No new matter is added by this process.

### CONCLUSION

The application is believed to be in condition for allowance. A prompt and favorable action the merits of the application is earnestly solicited.

Respectfully submitted,

  
\_\_\_\_\_  
Mitchell Bernstein, Ph.D.  
Registration No. 46,550  
Agent for Applicants

DARBY & DARBY P.C.  
Post Office Box 5257  
New York, NY 10150-5257  
212-527-7700